Abstract
To the Editor. —Albright et al 1 detail the clinical usefulness of intrathecal baclofen for treating spasticity in patients with cerebral palsy as a more effective alternative to oral administration. However, one disadvantage with this approach, as with other pharmacological modes of treatment, is the potential for simultaneous elimination of forms of spasticity. Excessive spasticity reduction in the lower-extremity antigravity muscles may significantly diminish the ability of the patient with spasticity to ambulate. Aptly labeled physiological crutch in certain clinical instances, spasticity can enable the patient with central nervous system injury to walk and to achieve optimal functional recovery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
